))
A podcast all about collected editions of the galaxy’s greatest comic 2000AD, hosted by Eamonn Clarke.
…
continue reading
A father and daughter podcast about the collected editions of Neil Gaiman's The Sandman comic
…
continue reading
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, and regulatory challenges you’ll face as you navigate your company from an idea to success in the clinic. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is p ...
…
continue reading
Podcast by Gareth A Hopkins Hosted on Acast. See acast.com/privacy for more information.
…
continue reading
1
Expanding The Proteome with ProFound's John Lepore, M.D.
56:38
56:38
Play later
Play later
Lists
Like
Liked
56:38
We love to hear from our listeners. Send us a message. Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome, where it’s now studying the full compendium of …
…
continue reading
Tony Esmond returns to discuss the best Batman book of the year, and to touch on the huge subject of Italian comics. You can find Tony at Tribute Press, the Awesome Comics Podcast, Never Iron Anything, and as a columnist in American Nature Presents which you should be able to pick up in Gosh comics. You can hear the Devil's Trills on youtube. It's …
…
continue reading
1
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné
1:06:39
1:06:39
Play later
Play later
Lists
Like
Liked
1:06:39
We love to hear from our listeners. Send us a message. While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash their teeth, and question life choices, then-19-year-old Enrique Diloné ate those classes for lunch. They inspired him to earn a Seton Hall Ph.D. in chemistry, and to go to work as a big bio research sc…
…
continue reading
I'm joined by 2000AD artist and colourist John Charles to discuss his own comics and his new Kickstarter for Technofreak Apocrypha. Find Technofreak on Kickstarter, or find more details on the Facebook page You can find a list of all the upcoming books on the Facebook page, follow the podcast on instagram, Threads, Mastodon, and BlueSky. And email …
…
continue reading
1
First AI Antibody In Humans with Aulos' Aron Knickerbocker
1:08:52
1:08:52
Play later
Play later
Lists
Like
Liked
1:08:52
We love to hear from our listeners. Send us a message. Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its CEO. On this week's episode of the Business of Biotech podcast, we get an introspective walk through Aron Kinickerbocker's strategically-orchestrated career path, from his early days in the labs at Br…
…
continue reading
Rob Ellis joins the book club to make the case for Junker by Michael Fleisher, John Ridgway and Tim Perkins. This episode was recorded at Lawless 2024, see you at next year's convention. You can find a list of all the upcoming books on the Facebook page, follow the podcast on instagram, Threads, Mastodon, and BlueSky. And email me comments and sugg…
…
continue reading
1
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
1:12:31
1:12:31
Play later
Play later
Lists
Like
Liked
1:12:31
We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. …
…
continue reading
1
Topical Ocular Biologics with Claris Bio's Clarke Atwell
58:06
58:06
Play later
Play later
Lists
Like
Liked
58:06
We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if succ…
…
continue reading
I met up with Giles Wright at the Lawless convention to discuss another eclectic mix of Judge Dredd stories from some masters of the form. We talk about how Dredd's world reflects our own concerns about policing, and then take some time to run through the highlights of Lawless. This collection is out of print but it is available digitally from that…
…
continue reading
1
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley
1:04:02
1:04:02
Play later
Play later
Lists
Like
Liked
1:04:02
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting fo…
…
continue reading
Pat Mills! The creator of 2000AD and so much more joins me to discuss his book Pageturners and his advice for creators who want to follow in his mighty footsteps. We also talk about his own first comic book reading experiences, and his latest and upcoming projects. You can buy a copy from the Millsverse Gumroad shop, and follow Pat on his Iconoblas…
…
continue reading
1
True DEI Value in Biopharma with Arcellx's Rami Elghandour
1:04:08
1:04:08
Play later
Play later
Lists
Like
Liked
1:04:08
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to …
…
continue reading
Richard Sheaf returns to the book club at the Lawless convention in Bristol to discuss the wonderful Bojeffries Saga by Alan Moore and Steve Parkhouse. You can find Richard's blog at BoysAdventureComics.blogspot.com including his entries about Steve Parkhouse and his Bruno Brooks cover. There's also his entry about the Bojeffries Saga, and head ove…
…
continue reading
1
Mission-Driven Dementia Funding with DDF's Jonathan Behr
55:46
55:46
Play later
Play later
Lists
Like
Liked
55:46
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-f…
…
continue reading
Conrad and I have been to the movies and we have thoughts about the lows of Madame Web and the heights of Furiosa: A Mad Max Saga. Mild spoilers for Madame Web. If you have a film double bill for the film club please get in touch. And head to SpaceSpinner2000.com for more great stuff as the boys are back in town! You can find a list of all the upco…
…
continue reading
1
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
1:04:06
1:04:06
Play later
Play later
Lists
Like
Liked
1:04:06
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership …
…
continue reading
Ashley Baker joins me from Japan to discuss one of the lesser known classics from the prog in the 1990s. Follow us into the world of John Smith and Paul Marshall's Firekind, and get your copy from the 2000AD store. Also if you need Japanese translation services contact akt.honyaku@gmail.com You can find a list of all the upcoming books on the Faceb…
…
continue reading
1
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D.
56:38
56:38
Play later
Play later
Lists
Like
Liked
56:38
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, …
…
continue reading
1
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch
57:35
57:35
Play later
Play later
Lists
Like
Liked
57:35
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…
…
continue reading
Keith Richardson is the senior graphic novels editor at Rebellion and the editor of Monster Fun. We take a break from classic British comics to divert into the wonderful world of funny animals with Captain Carrot and his Amazing Zoo Crew. And then we catch up with some exciting current and upcoming releases from the Treasury of British Comics. You …
…
continue reading
1
A New Prescription For PBMs with Allan Shaw
40:13
40:13
Play later
Play later
Lists
Like
Liked
40:13
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …
…
continue reading
I spoke to Su Haddrell about her work organising the superb Lawless convention for the last ten years. This year's event is on May 25-26th at the Doubletree Hilton in Bristol. Find tickets at Lawlesscomiccon.co.uk and also support this year's charity at Rewriting.earth. You can find a list of all the upcoming books on the Facebook page, follow the …
…
continue reading
1
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim
59:10
59:10
Play later
Play later
Lists
Like
Liked
59:10
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …
…
continue reading
Sloe Smycz joins me from Warsaw to discuss reading British comics in Poland, and to focus on a fascinating mix of skateboarding and Pat Mills' politics from the pages of Jinty. We talk about Pat's involvement in creating Jinty and writing this story, and the wonderful black and white artwork by Christine Ellingham. Check out the Warsaw Avangarda or…
…
continue reading
1
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch
59:11
59:11
Play later
Play later
Lists
Like
Liked
59:11
We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …
…
continue reading
1
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.
1:01:30
1:01:30
Play later
Play later
Lists
Like
Liked
1:01:30
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…
…
continue reading
Colin Maxwell is a comic book creator who writes for Commando comics, and he joins the book club to discuss a recent collection of a classic story from DC Thomson in the 1970s. Find Colin at Maximised Comics and on Instagram. You can find a list of all the upcoming books on the Facebook page, follow the podcast on instagram, Threads, Mastodon, and …
…
continue reading
1
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D.
56:54
56:54
Play later
Play later
Lists
Like
Liked
56:54
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…
…
continue reading
Alan Fisher returns to talk me through Bryan Talbot's memoir which he helped design, and to tell me about the new Johnny Alpha statue which you can still buy from Fish Collectibles. Also check out Keith Gainham's Strontium Dog page on Facebook. You can find a list of all the upcoming books on the Facebook page, follow the podcast on instagram, Thre…
…
continue reading
1
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil.
49:47
49:47
Play later
Play later
Lists
Like
Liked
49:47
We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…
…
continue reading
The comic artist Stref AKA Stephen White joins me to discuss the Comic Scene kickstarter for his new graphic novel Tara Togs: The Silence of Unicorns. Follow the link for the kickstarter, find Stephen on his website, instagram and the Tara Togs Facebook page. You can find a list of all the upcoming books on the Facebook page, follow the podcast on …
…
continue reading
1
Funding Alzheimer's Tx Dev with ADDF's Karen Harris
40:16
40:16
Play later
Play later
Lists
Like
Liked
40:16
We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…
…
continue reading
Troy Martin joins the film club to explore 2000AD connections with the Tom Selleck robot movie Runaway, and then to ask whether Skizz is better than E.T. the Extra-terrestial. You can find Conrad at SpaceSpinner2000.com and check out Troy's comics work at Sweet Nightmares Media, and find him on his fitness site TMfitness.co.uk You can find a list o…
…
continue reading
1
The AI Impact with Generate:Biomedicines' Mike Nally
1:13:54
1:13:54
Play later
Play later
Lists
Like
Liked
1:13:54
We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersecti…
…
continue reading
Tim Burnell returns to the book club with one of the earliest collaborations between Ed Brubaker and Sean Phillips. We recorded this episode in the pub and it's a bit noisy. You can find Tim's own work in DUI #3 on the GlobalComix app and follow his ongoing art project @timotron1on Instagram. You can find a list of all the upcoming books on the Fac…
…
continue reading
1
Strategic Deals with CinRx's Gavin Samuels, M.D.
47:52
47:52
Play later
Play later
Lists
Like
Liked
47:52
We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business d…
…
continue reading
1
Serial Success With Triumvira's Rob Williamson
31:32
31:32
Play later
Play later
Lists
Like
Liked
31:32
We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson is…
…
continue reading
Peter McKinney joins the book club to help me tackle the most controversial strip in the history of the galaxy's greatest comic. It's time to talk about Big Dave by Grant Morrison, Mark Millar and Steve Parkhouse. You can find Peter's blog post about the comic at the Hindsight Hut. And the other two articles we mention are by Colin Smith on Sequart…
…
continue reading
1
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D.
50:43
50:43
Play later
Play later
Lists
Like
Liked
50:43
We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challen…
…
continue reading
1
Precision Radiopharmaceuticals with Ratio's Jack Hoppin, Ph.D.
40:38
40:38
Play later
Play later
Lists
Like
Liked
40:38
We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necess…
…
continue reading
Broadcasting on the Voice of Fate Giles Richards returns to discuss one of the all-time classics: V for Vendetta by Alan Moore and David Lloyd. We talk about some of the very emotional moments in this book with spoilers for some big reveals. Pray the future will never need V for Vendetta! Find Giles on The Gurdian and order his new book F1 Racing C…
…
continue reading
1
Managing Mergers With Sail Biomedicines' Guillaume Pfefer, Ph.D.
51:07
51:07
Play later
Play later
Lists
Like
Liked
51:07
We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its programmable medicine platform companies. What you likely haven’t heard is the inside story on how the merger w…
…
continue reading
The film club is back as Giles "Snake" Richards helps us Escape from New York and makes the connection between one of John Carpenter's finest films and the prog. We also try and spring Conrad from LA in the sequel. You can find Giles at The Guardian, and order his new book about Formula One. You can find the theme song remix by King DJ that we disc…
…
continue reading
1
Reprogramming Human Cells With bit.bio's Mark Kotter, M.D.
45:51
45:51
Play later
Play later
Lists
Like
Liked
45:51
We love to hear from our listeners. Send us a message. The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scientists) on the entire journey from discovery to commercial. Bit.bio is exemplary of this new breed. Its CEO,…
…
continue reading
Colin "YNWA" Taylor returns to help me tick off another great British comic as we consider the success, the style, and the humour of The Phoenix. Track down a Colossal collection or some of the many Bunny vs Monkey books. And check out Colin's own project of 133 great comic book runs you should read on the 2000AD forums. You can find a list of all …
…
continue reading
1
Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.
46:59
46:59
Play later
Play later
Lists
Like
Liked
46:59
We love to hear from our listeners. Send us a message. Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. Having acknowledged that, no first iterat…
…
continue reading
I was lucky enough to attend this year's Angouleme festival in France, and while there I met with Tony "LeMonde" Esmond for a croissant and a chat about the festival experience, some key creators, and a fantastic book from NoBrow Press. Follow Tony's comic book adventures at Never Iron Anything, and check out his visitors' guide to the festival on …
…
continue reading
We love to hear from our listeners. Send us a message. The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech builders. The results of that trip will feed the next several weeks of Business of Biotech podcast programmin…
…
continue reading
Jim O'Brien joins the book club to introduce me to the work of the great European comic book artist Hugo Pratt. We start with the Night of the Devil collection from the Treasury of British Comics, and then cover some of his other works. You can find Jim's own writings about the history of comics in Justin Marriott's Battling Britains and in Comics …
…
continue reading
1
Multimodal R&D Management with Incyte's Jim Lee, M.D., Ph.D.
50:31
50:31
Play later
Play later
Lists
Like
Liked
50:31
We love to hear from our listeners. Send us a message. Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of …
…
continue reading
